Sangamo Therapeutics, Inc. (SGMO) Director Saira Ramasastry Sells 5,000 Shares

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Director Saira Ramasastry sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Friday, November 17th. The shares were sold at an average price of $14.67, for a total transaction of $73,350.00. Following the transaction, the director now owns 5,000 shares in the company, valued at approximately $73,350. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Sangamo Therapeutics, Inc. (NASDAQ SGMO) traded down $0.07 during mid-day trading on Wednesday, reaching $15.03. 720,575 shares of the company’s stock were exchanged, compared to its average volume of 1,294,683. Sangamo Therapeutics, Inc. has a 52-week low of $2.65 and a 52-week high of $17.06. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The firm had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. During the same quarter in the previous year, the business posted ($0.27) EPS. The firm’s revenue was up 333.0% compared to the same quarter last year. sell-side analysts forecast that Sangamo Therapeutics, Inc. will post -0.79 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Sangamo Therapeutics, Inc. (SGMO) Director Saira Ramasastry Sells 5,000 Shares” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/22/sangamo-therapeutics-inc-sgmo-director-saira-ramasastry-sells-5000-shares.html.

SGMO has been the topic of several recent research reports. BidaskClub lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Piper Jaffray Companies set a $8.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a report on Thursday, August 10th. ValuEngine upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Friday, August 18th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $30.00 target price (up previously from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $17.83.

Hedge funds have recently modified their holdings of the business. HighTower Advisors LLC increased its position in shares of Sangamo Therapeutics by 0.3% in the 1st quarter. HighTower Advisors LLC now owns 39,405 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 100 shares during the last quarter. Blair William & Co. IL increased its position in shares of Sangamo Therapeutics by 4.3% in the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 500 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Sangamo Therapeutics by 0.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock worth $670,000 after purchasing an additional 513 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Sangamo Therapeutics by 6.8% in the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 832 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Sangamo Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock worth $2,353,000 after purchasing an additional 1,558 shares during the last quarter. Hedge funds and other institutional investors own 63.29% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

What are top analysts saying about Sangamo Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sangamo Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit